Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9705 |
TL-895
|
BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
TL-895 是口服有效的,ATP 竞争性的,以及高度选择性和不可逆的BTK 抑制剂,IC50和Ki 分别为 1.5 nM 和 11.9 nM。TL-895在 JAKi 复发/难治性骨髓纤维化、急性髓系白血病、COVID-19 和癌症方面有研究的价值。 | |||
T3069 |
AZD-1480
|
JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells |
AZD1480 是 ATP 竞争型JAK1和JAK2抑制剂,IC50分别为 1.3 和 0.4 nM。 | |||
T2709 |
TAK-901
TAK901 |
JAK; CDK; Src; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
TAK-901是一种多靶点的极光激酶抑制剂,对极光激酶 A 和 B 的 IC50值分别为 21 和 15 nM。它用于研究淋巴瘤、骨髓纤维化、多发性骨髓瘤、骨髓化生和晚期实体瘤等治疗的试验。 | |||
T70823 |
Momelotinib HCl
|
||
Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients. | |||
T11687 |
Itacitinib adipate
|
Phosphatase | Metabolism |
Itacitinib adipate is an orally bioavailable and selective JAK1 inhibitor,Itacitinib adipate has been tested for efficacy and safety in a phase II trial in myelofibrosis. | |||
T64283 | Pacritinib hydrochloride | ||
Pacritinib hydrochloride 是一种野生型 JAK2 (IC50: 23 nM) 和 JAK2V617F 突变型 (IC50: 19 nM) 的有效抑制剂。Pacritinib hydrochloride 也能够抑制 FLT3 (IC50: 22 nM) 及其突变型 FLT3D835Y (IC50: 6 nM)。Pacritinib hydrochloride 能够用于研究急性髓系白血病(AML)和骨髓纤维化(MF)。 | |||
T70008 |
Bomedemstat ditosylate
|
||
Bomedemstat, also known as IMG-7289, is a lysine-specific histone demethylase 1 (LSD1) inhibitor with antineoplastic activity. Bomedemstat may be useful in the treatment of acute myeloid leukaemia, myelodysplastic syndrome, and Myelofibrosis. IMG-7289 selectively inhibited proliferation and induced apoptosis of JAK2 V617F cells by concomitantly increasing expression and methylation of p53, and, independently, the pro-apoptotic factor PUMA and by decreasing the levels of its antiapoptotic antago... | |||
T9634 |
Bomedemstat
|
||
Bomedemstat (IMG-7289) 是一种有效的,具有口服活性的且不可逆的赖氨酸特异性脱甲基酶 1 (LSD1) 抑制剂,具有表观遗传活性。Bomedemstat 具有抗癌活性,可用于急性髓性白血病 (AML) 和骨髓纤维化 (MF) 的研究。 |